Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Committed to advancing new medicines to benefit patients with viral-associated cancers and other serious diseases.

Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Recent News

Viracta Announces Appointment of Lisa Rojkjaer, MD, as Chief Medical Officer

Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Lisa Rojkjaer, MD, as Chief Medical Officer (CMO), effective May 1, 2020. Read More

Viracta's Precision Oncology Research in EBV+ Cancers Highlighted at 16th Annual UCSD Moores Cancer Center Symposium

Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, announced today that Ivor Royston, M.D., the Company's President and CEO, will present an overview of Viracta's approach in treating patients with Epstein-Barr Virus (EBV)-associated malignancies and data from the ongoing Phase 2 clinical trial in lymphoma. Read More

Viracta Therapeutics to Present at the 2020 BIO CEO & Investor Conference

Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, announced today that Dan Chevallard, Chief Financial Officer of Viracta, will present a company overview at the 2020 BIO CEO and Investor Conference on Tuesday, February 11, 2020 at 2:30 pm ET in New York, NY. Read More

Viracta Announces Positive Phase 1b/2 Data Presented at Oral Presentation on Lead Program for Epstein-Barr Virus (EBV)-associated Relapsed/Refractory Lymphomas at the 2019 American Society of Hematology (ASH) Annual Meeting

Phase 1b Overall Objective Response Rate (ORR) of 56% Including 28% Complete Response (CR) - Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, announced today that its lead investigator, Dr. Pierluigi Porcu of the Sidney Kimmel Cancer Center, Thomas Jefferson University, presented new clinical data from the Company’s Phase 1b/2a clinical trial of the orally administered combination of nanatinostat (Nstat) in combination with the antiviral valganciclovir for the treatment of EBV-associated relapsed/refractory lymphomas. Read More

Viracta Therapeutics to Present at the Evercore ISI HealthCONx Conference

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will present a company overview at the Evercore ISI HealthCONx Conference on Wednesday, December 4, 2019 at 2:45 pm ET in Boston, MA. Read More

Events

February 25-27, 2020

Biocom's 10th Annual Global Life Science Partnering Conference, in La Jolla, CA Read More

February 20, 2020

16th Annual UCSD Moores Cancer Center Symposium, in San Diego, CA Read More

February 11, 2020

2020 BIO CEO and Investor Conference on Tuesday, February 11, 2020 in New York, NY Read More

December 4, 2019

Evercore ISI HealthCONx Conference, Boston, MA Read More

Recent News

Viracta Announces Appointment of Lisa Rojkjaer, MD, as Chief Medical Officer

Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Lisa Rojkjaer, MD, as Chief Medical Officer (CMO), effective May 1, 2020. Read More

Viracta's Precision Oncology Research in EBV+ Cancers Highlighted at 16th Annual UCSD Moores Cancer Center Symposium

Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, announced today that Ivor Royston, M.D., the Company's President and CEO, will present an overview of Viracta's approach in treating patients with Epstein-Barr Virus (EBV)-associated malignancies and data from the ongoing Phase 2 clinical trial in lymphoma. Read More

Viracta Therapeutics to Present at the 2020 BIO CEO & Investor Conference

Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, announced today that Dan Chevallard, Chief Financial Officer of Viracta, will present a company overview at the 2020 BIO CEO and Investor Conference on Tuesday, February 11, 2020 at 2:30 pm ET in New York, NY. Read More

Viracta Announces Positive Phase 1b/2 Data Presented at Oral Presentation on Lead Program for Epstein-Barr Virus (EBV)-associated Relapsed/Refractory Lymphomas at the 2019 American Society of Hematology (ASH) Annual Meeting

Phase 1b Overall Objective Response Rate (ORR) of 56% Including 28% Complete Response (CR) - Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, announced today that its lead investigator, Dr. Pierluigi Porcu of the Sidney Kimmel Cancer Center, Thomas Jefferson University, presented new clinical data from the Company’s Phase 1b/2a clinical trial of the orally administered combination of nanatinostat (Nstat) in combination with the antiviral valganciclovir for the treatment of EBV-associated relapsed/refractory lymphomas. Read More

Viracta Therapeutics to Present at the Evercore ISI HealthCONx Conference

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will present a company overview at the Evercore ISI HealthCONx Conference on Wednesday, December 4, 2019 at 2:45 pm ET in Boston, MA. Read More

Events

February 20, 2020

16th Annual UCSD Moores Cancer Center Symposium, in San Diego, CA Read More

February 25-27, 2020

Biocom's 10th Annual Global Life Science Partnering Conference, in La Jolla, CA Read More

February 11, 2020

2020 BIO CEO and Investor Conference on Tuesday, February 11, 2020 in New York, NY Read More

December 4, 2019

Evercore ISI HealthCONx Conference, Boston, MA Read More